Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Cross

Orthopaedic Surgery Indianapolis, IN Medical Doctor

NPI 1235397043 CMS profile 237698

8450 Northwest Blvd, Indianapolis, IN 46278

Open in the dashboard

General payments

$870,255

480 records reported · program years 2019–2025

Research payments

$2,500

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$139,060

7 holdings reported · through program year 2025

Research they led as principal investigator

$18,477 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Michael Cross of Indianapolis, IN is reported in the CMS Open Payments database as having received $870,255 across 480 general payments and $2,500 in research payments paid to them. Separately, studies naming them as principal investigator received $18,477 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $139,060 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

15 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $78,736 58
2024 General $115,419 115
2023 General $204,216 42
2022 General $151,943 97
2021 General $143,379 44
2020 General $30,776 25
2019 General $145,785 99
2019 Research $2,500 1
2025 Ownership $125,370 1
2024 Ownership $2,282 1
2023 Ownership $2,282 1
2022 Ownership $2,282 1
2021 Ownership $2,282 1
2020 Ownership $2,282 1
2019 Ownership $2,282 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Cross
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Michael Cross were reported at $78,736. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Michael Cross Orthopaedic Surgery median Middle half National median
2019 $145,785 $644 $140–$2,844 $163
2020 $30,776 $312 $75–$1,860 $114
2021 $143,379 $520 $117–$2,495 $132
2022 $151,943 $598 $128–$2,731 $149
2023 $204,216 $461 $128–$2,264 $160
2024 $115,419 $497 $134–$2,475 $164
2025 $78,736 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. DePuy Synthes Products, Inc. $294,116 111 payments
  2. Medical Device Business Services, Inc. $204,879 132 payments
  3. KCI USA, Inc $115,897 68 payments
  4. Encore Medical, LP $89,782 1 payment
  5. Smith+Nephew, Inc. $57,522 51 payments
  6. Flexion Therapeutics, Inc. $47,153 38 payments
  7. Exactech, Inc. $26,535 33 payments
  8. LinkBio Corp $20,324 8 payments
  9. Solventum Corporation $10,137 7 payments
  10. Alphatec Spine, Inc $2,000 2 payments
  11. Other $1,911 29 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $397,124 138 payments
  2. Royalty or License $211,468 5 payments
  3. Acquisitions $89,782 1 payment
  4. Travel and Lodging $59,691 130 payments
  5. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $56,633 17 payments
  6. Honoraria $37,625 10 payments
  7. Food and Beverage $10,189 175 payments
  8. Compensation for serving as faculty or as a speaker for a medical education program $6,580 1 payment
  9. Education $550 1 payment
  10. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $500 1 payment
  11. Other $114 1 payment
Products named General payments · program years 2019–2025
  1. ATTUNE Ortho-Knee $207,201 124 payments
  2. PREVENA Non-Covered $65,613 25 payments
  3. PREVENA Negative Pressure Systems & Dressings $56,141 32 payments
  4. Zilretta $47,153 38 payments
  5. ATTUNE Ortho-Knee $36,116 41 payments
  6. REAL INTELLIGENCE $29,017 31 payments
  7. JOURNEY II $25,108 21 payments
  8. PREVENA RESTOR ARTHROFORM $24,003 13 payments
  9. K-15 PORK $21,994 2 payments
  10. V.A.C. VERAFLO $18,191 18 payments
  11. Other $242,505 238 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Exactech, Inc. $2,500 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

1,134

Median for Orthopedic Surgery: 203

Drug cost

$40,085

Median for Orthopedic Surgery: $1,433

Branded share of claims

9.9%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 62 $31,871
Diclofenac Sodium Generic 271 $2,719
Oxycodone Hcl Generic 322 $1,979
Cefadroxil Generic 162 $1,794
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 38 $374
Celecoxib Generic 29 $318
Doxycycline Hyclate Generic 19 $208
Meloxicam Generic 48 $198
Tramadol Hcl Generic 51 $177
Ondansetron Odt Ondansetron Brand 12 $139

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 38 billing codes

Paid by Medicare

$136,683

Of which drugs: $2,843

Medicare patients

344

Average age 74

Services billed

10,928

219 women, 125 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Depression 28%
Diabetes 24%
Ischemic heart disease 24%
Atrial fibrillation 17%
Chronic kidney disease 17%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 62 9,800 $988
Injection, methylprednisolone acetate, 80 mg J1040 Office 24 31 $123

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

481 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record